Lyell Immunopharma share price today

(LYEL)

Lyell Immunopharma share price is $0.68 & ₹58.35 as on 7 Jan 2025, 2.30 'hrs' IST

$0.68

▲

-0.02

(-2.85%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Lyell Immunopharma share price in Dollar and Rupees. Guide to invest in Lyell Immunopharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Lyell Immunopharma, along with analyst recommendations, forecasts, and comprehensive financials.

Lyell Immunopharma share price movements

Today's Low: $0.67
Today's High: $0.71
$0.68
1.37%
Downside
Day's Volatility :5.87%
Upside
4.56%
52 Weeks Low: $0.58
52 Weeks High: $3.26
$0.68
14.47%
Downside
52 Weeks Volatility :82.14%
Upside
79.11%

Lyell Immunopharma Returns

Period	Lyell Immunopharma, Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-38.24%	-8.4%	0.0%
6 Months	-56.38%	-3.8%	0.0%
1 Year	-67.08%	-0.1%	0.0%
3 Years	-89.46%	2.9%	-19.8%

Lyell Immunopharma Key Statistics

in dollars & INR

Previous Close	$0.6979
Open	$0.707
Today's High	$0.7125
Today's Low	$0.6707
Market Capitalization	$187.0M
Today's Volume	$814.4K
52 Week High	$3.2556
52 Week Low	$0.5816
Revenue TTM	$63.0K
EBITDA	$-196.6M
Earnings Per Share (EPS)	$-0.79
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-33.22%

How to invest in Lyell Immunopharma from India?

It is very easy for Indian residents to invest directly in Lyell Immunopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Lyell Immunopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Lyell Immunopharma or LYEL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Lyell Immunopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Lyell Immunopharma shares which would translate to 1.262 fractional shares of Lyell Immunopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Lyell Immunopharma, in just a few clicks!

Returns in Lyell Immunopharma for Indian investors in Rupees

Investment Value

₹1,00,000

Lyell Immunopharma investment value today

Current value as on today

₹35,298

Returns

₹64,702

(-64.7%)

Returns from Lyell Immunopharma Stock

₹67,925 (-67.92%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Lyell Immunopharma

142%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Lyell Immunopharma on INDmoney from India has grown in the last 30 days as on Jan 7, 2025. 142% more investors are searching Lyell Immunopharma in the last 30 days versus the previous period.

Global Institutional Holdings in Lyell Immunopharma

MWG Management Ltd.
6.90%
Orland Properties Ltd
5.17%
BlackRock Inc
4.62%
Vanguard Group Inc
3.45%
Foresite Capital Management IV, LLC
2.85%
Wuxi AppTec Co Ltd
2.53%

Analyst Recommendation on Lyell Immunopharma

Buy

70%Buy

30%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Lyell Immunopharma(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Lyell Immunopharma

What analysts predicted

Upside of 47.06%

Current:

$0.68

Target:

$1.00

Insights on Lyell Immunopharma

Price Movement
In the last 7 days, LYEL stock has moved up by 12.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 3.0K → 34.0K (in $), with an average increase of 69.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -60.66M → -44.58M (in $), with an average increase of 17.6% per quarter
LYEL vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 89.5%
LYEL vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 144.4%

Lyell Immunopharma Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$657.0K	-
Net Income	$-121.3M	-
Net Profit Margin	-18.5K%	-

	FY20	Y/Y Change
Revenue	$7.8M	↑ 1080.52%
Net Income	$-198.5M	↑ 63.73%
Net Profit Margin	-2.6K%	↑ 15896.28%

	FY21	Y/Y Change
Revenue	$10.7M	↑ 37.31%
Net Income	$-285.5M	↑ 43.81%
Net Profit Margin	-2.7K%	↓ 121.03%

	FY22	Y/Y Change
Revenue	$84.7M	↑ 695.15%
Net Income	$-4.8M	↓ 98.33%
Net Profit Margin	-5.61%	↑ 2675.15%

	FY23	Y/Y Change
Revenue	$130.0K	↓ 99.85%
Net Income	$-234.6M	↑ 4835.46%
Net Profit Margin	-180.5K%	↓ 180480.54%

	Q2 FY23	Q/Q Change
Revenue	$27.0K	↓ 58.46%
Net Income	$-63.9M	↓ 51.83%
Net Profit Margin	-236.6K%	↓ 32583.48%

	Q3 FY23	Q/Q Change
Revenue	$25.0K	↓ 7.41%
Net Income	$-50.9M	↓ 20.41%
Net Profit Margin	-203.4K%	↑ 33217.63%

	Q4 FY23	Q/Q Change
Revenue	$13.0K	↓ 48.0%
Net Income	$-52.9M	↑ 4.08%
Net Profit Margin	-407.2K%	↓ 203741.85%

	Q1 FY24	Q/Q Change
Revenue	$3.0K	↓ 76.92%
Net Income	$-60.7M	↑ 14.62%
Net Profit Margin	-2.0M%	↓ 1615079.48%

	Q2 FY24	Q/Q Change
Revenue	$13.0K	↑ 333.33%
Net Income	$-45.8M	↓ 24.49%
Net Profit Margin	-352.4K%	↑ 1669856.41%

	Q3 FY24	Q/Q Change
Revenue	$34.0K	↑ 161.54%
Net Income	$-44.6M	↓ 2.68%
Net Profit Margin	-131.1K%	↑ 221250.45%

	FY19	Y/Y Change
Profit	$657.0K	-

	FY20	Y/Y Change
Profit	$281.0K	↓ 57.23%

	FY21	Y/Y Change
Profit	$-3.9M	↓ 1482.56%

	FY22	Y/Y Change
Profit	$68.2M	↓ 1855.88%

	FY23	Y/Y Change
Profit	$130.0K	↓ 99.81%

	Q2 FY23	Q/Q Change
Profit	$-4.5M	↓ 9.07%

	Q3 FY23	Q/Q Change
Profit	$-5.1M	↑ 12.57%

	Q4 FY23	Q/Q Change
Profit	$-5.0M	↓ 0.69%

	Q1 FY24	Q/Q Change
Profit	$-5.0M	↓ 0.46%

	Q2 FY24	Q/Q Change
Profit	$-4.9M	↓ 2.65%

	Q3 FY24	Q/Q Change
Profit	$34.0K	↓ 100.7%

	FY19	Y/Y Change
Operating Cash Flow	$39.5M	-
Investing Cash Flow	$-422.4M	-
Financing Cash Flow	$351.2M	-

	FY20	Y/Y Change
Operating Cash Flow	$-160.9M	↓ 507.54%
Investing Cash Flow	$-273.5M	↓ 35.25%
Financing Cash Flow	$476.8M	↑ 35.78%

	FY21	Y/Y Change
Operating Cash Flow	$-126.2M	↓ 21.52%
Investing Cash Flow	$-121.6M	↓ 55.55%
Financing Cash Flow	$401.2M	↓ 15.84%

	FY22	Y/Y Change
Operating Cash Flow	$-169.6M	↑ 34.3%
Investing Cash Flow	$-11.5M	↓ 90.51%
Financing Cash Flow	$10.6M	↓ 97.35%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-39.2M	↓ 15.26%
Investing Cash Flow	$152.9M	↑ 375.56%
Financing Cash Flow	$1.2M	↓ 1833.33%

Lyell Immunopharma Technicals Summary

Sell

Neutral

Buy

Lyell Immunopharma is currently in a neutral trading position according to technical analysis indicators.

Lyell Immunopharma Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Lyell Immunopharma, Inc	-22.46%	-56.38%	-67.08%	-89.46%	-95.87%
Regeneron Pharmaceuticals, Inc.	-8.86%	-31.87%	-20.46%	15.59%	87.28%
Biontech Se	-4.16%	43.82%	3.49%	-49.66%	167.6%
Alnylam Pharmaceuticals, Inc.	-8.45%	-8.03%	19.03%	56.02%	98.44%
Vertex Pharmaceuticals Incorporated	-14.11%	-16.23%	-2.87%	81.78%	76.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Lyell Immunopharma, Inc	1.78	NA	NA	-0.58	-0.33	-0.19	NA	2.07
Regeneron Pharmaceuticals, Inc.	17.61	17.61	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Lyell Immunopharma, Inc	Buy	$187.0M	-95.87%	1.78	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$78.3B	87.28%	17.61	33.61%
Biontech Se	Buy	$27.3B	167.6%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	98.44%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$103.7B	76.8%	32.84	-4.51%

About Lyell Immunopharma

we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.

Organization	Lyell Immunopharma
Employees	224
CEO	Dr. Richard D. Klausner M.D.
Industry	Services

Management People of Lyell Immunopharma

Name	Title
Dr. Richard D. Klausner M.D.	Founder & Executive Chairman
Dr. Lynn Seely M.D., Ph.D.	President, CEO & Director
Mr. Charles W. Newton	Chief Financial Officer
Mr. Stephen J. Hill	Chief Operating Officer
Dr. Gary Lee Ph.D.	Chief Scientific Officer
Mr. Matthew Lang J.D.	Chief Business Officer, Chief Legal Officer & Corporate Secretary
Prof. Stanley R. Riddell M.D.	Founder & Scientific Advisor
Dr. Crystal L. Mackall M.D.	Founder & Scientific Advisor
Nellie Dillery	Director of Accounting
Ms. Ellen Rose	Senior Vice President of Communications & Investor Relations

Important FAQs about investing in Lyell Immunopharma from India :

What is Lyell Immunopharma share price today?

Lyell Immunopharma share price today stands at $0.68, Open: $0.71 ; Previous Close: $0.70 ; High: $0.71 ; Low: $0.67 ; 52 Week High: $3.26 ; 52 Week Low: $0.58. The stock opens at $0.71, after a previous close of $0.70. The stock reached a daily high of $0.71 and a low of $0.67, with a 52-week high of $3.26 and a 52-week low of $0.58.

Can Indians buy Lyell Immunopharma shares?

Yes, Indians can invest in the Lyell Immunopharma (LYEL) from India.

With INDmoney, you can buy Lyell Immunopharma at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Lyell Immunopharma at zero transaction cost.

How can I buy Lyell Immunopharma shares from India?

It is very easy to buy Lyell Immunopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Lyell Immunopharma be purchased?

Yes, you can buy fractional shares of Lyell Immunopharma with INDmoney app.

What are the documents required to start investing in Lyell Immunopharma stocks?

To start investing in Lyell Immunopharma, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.